Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants
Summary
The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) treatment in Thai schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) participants.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-09
- Completion
- 2010-09
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Paliperidone Extended Release (ER); p = 0.000; Friedman test NCT01387542 ↗
registry analysis (superiority or other test); Paliperidone Extended Release (ER); p = 0.009; Paired t-test NCT01387542 ↗
registry analysis (superiority or other test); Paliperidone Extended Release (ER); p = 0.001; Paired t-test NCT01387542 ↗
registry analysis (superiority or other test); Paliperidone Extended Release (ER); p = 0.000; Paired t-test NCT01387542 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone extended release (ER) | Unknown | 3 mg | Oral |
| Subject | Paliperidone extended release (ER) | Unknown | 6 mg | Oral |
| Subject | Paliperidone extended release (ER) | Unknown | 9 mg | Oral |
| Subject | Paliperidone extended release (ER) | Unknown | 12 mg | Oral |